Literature DB >> 24811726

Protective effect of an antithyroid compound against γ-radiation-induced damage in human colon cancer cells.

Marina Perona1, Maria A Dagrosa, Romina Pagotto, Mariana Casal, Omar Pignataro, Mario A Pisarev, Guillermo J Juvenal.   

Abstract

We have previously reported the radioprotective effect of propylthiouracil (PTU) on thyroid cells. The aim of the present study was to analyze whether tumor cells and normal cells demonstrate the same response to PTU. Human colon carcinoma cells were irradiated with γ-irradiation with or without PTU. We evaluated the clonogenic survival, intracellular reactive oxygen species levels, catalase, superoxide dismutase and glutathione peroxidase activities, and apoptosis by nuclear cell morphology and caspase-3 activity assays. Cyclic AMP (cAMP) levels were measured by radioimmunoassay. PTU treatment increased surviving cell fraction at 2 Gy (SF2) from 56.9 ± 3.6 in controls to 75.0 ± 3.5 (p < 0.05) and diminished radiation-induced apoptosis. In addition, we observed that the level of antioxidant enzymes' activity was increased in cells treated with PTU. Moreover, pretreatment with PTU increased intracellular levels of cAMP. Forskolin (p < 0.01) and dibutyryl cAMP (p < 0.05) mimicked the effect of PTU on SF2. Co-treatment with H89, an inhibitor of protein kinase A, abolished the radioprotective effect of PTU. PTU reduces the toxicity of ionizing radiation by increasing cAMP levels and also possibly through a reduction in apoptosis levels and in radiation-induced oxidative stress damage. We therefore conclude that PTU protects both normal and cancer cells during exposure to radiation in conditions mimicking the radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24811726     DOI: 10.1007/s00411-014-0542-9

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  39 in total

1.  Effect of pretreatment with methylthiouracil on results of I-131 therapy.

Authors:  J CROOKS; W W BUCHANAN; E J WAYNE; E MACDONALD
Journal:  Br Med J       Date:  1960-01-16

2.  Reduction in lethal effect of x-radiation by pretreatment with thiourea or sodium ethane dithiophosphonate.

Authors:  R H MOLE; J L PHILPOT; G R V HODGES
Journal:  Nature       Date:  1950-09-23       Impact factor: 49.962

Review 3.  Prooxidant states and tumor promotion.

Authors:  P A Cerutti
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

4.  Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial.

Authors:  Steen Joop Bonnema; Finn Noe Bennedbaek; Annegrete Veje; Jens Marving; Laszlo Hegedüs
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

5.  Cyclic 3'-5'-adenosine monophosphate: its possible role in mammalian cell mitosis and radiation-induced mitotic G2-delay.

Authors:  J F Scaife
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1971

6.  Radiosensitization and production of DNA double-strand breaks in U87MG brain tumor cells induced by tetraiodothyroacetic acid (tetrac).

Authors:  Aleck H Hercbergs; Hung-Yun Lin; Faith B Davis; Paul J Davis; John T Leith
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

7.  Nitric oxide inhibits Leydig cell steroidogenesis.

Authors:  K Del Punta; E H Charreau; O P Pignataro
Journal:  Endocrinology       Date:  1996-12       Impact factor: 4.736

Review 8.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

9.  Alteration in the glutathione, glutathione peroxidase, superoxide dismutase and lipid peroxidation by ascorbic acid in the skin of mice exposed to fractionated gamma radiation.

Authors:  Ganesh Chandra Jagetia; G K Rajanikant; Shaival K Rao; M Shrinath Baliga
Journal:  Clin Chim Acta       Date:  2003-06       Impact factor: 3.786

Review 10.  Radioprotection.

Authors:  Joel S Greenberger
Journal:  In Vivo       Date:  2009 Mar-Apr       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.